For Healthcare Professionals
Soma Carisoprodol 250 - Relief without compromise
Soma Carisoprodol 250 - Relief without compromise

Important Information

Patient Prescribing Information

Know the Facts: SOMA® 250 mg
On this page:
Know the Facts: SOMA®250 mg
Compare the Facts: Safety

  • NON-narcotic
  • NO food effects (maybe taken with or without food)
  • NO precautionary liver tests required1
  • NO adjunctive rest or physical therapy requirements1
  • In clinical trials, NO anticholinergic effects, including urinary retention, were reported in ≥ 2% of patients.


Compare the Facts: Safety

Maximum Exposure To Meprobamate

  • SOMA and one of its metabolites may cause dependence
  • Meprobamate levels are nearly 4½ times less after taking SOMA 250 mg (carisoprodol) than after taking a single 400 mg tablet of meprobamate1-2
  • The majority of cases of abuse and/or dependence were reported when carisoprodol was used in combination with other medications with abuse potential
  • There have been post-marketing adverse event reports of SOMA-associated abuse when used without other drugs with abuse potential

* Concentration data are from separate single-dose pharmacokinetic studies. No direct comparison has been evaluated in clinical trials.


1. SOMA 250 mg [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2007.
2. Meyer MC, Melikian AP, Straughn AB, Relative bioavailability of meprobamate tablets in humans, J Pharm Sci. 1978;67(9): 1290-93
SOMA 250(carisoprodol): Know the Facts

1. SOMA [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2007
2. Data on file. Meda Pharmaceuticals Inc.


  • SOMA (carisoprodol) is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.
  • SOMA should be used for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.

Important Safety Information:

  • SOMA is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate.
  • Patients should be advised that SOMA may cause drowsiness and/or dizziness and has been associated with motor vehicle accidents. Patients should advised to avoid using SOMA before engaging in potentially hazardous activities.
  • Since the effects of SOMA and CNS depressants (including alcohol) or psychotropic drugs may be additive, appropriate caution should be exercised with patients who take more than one of these agents simultaneously.
  • In postmarketing experience with SOMA, cases of dependence, withdrawal, and abuse have been reported with prolonged use. SOMA should be used with caution in addiction-prone patients.
  • There have been postmarketing reports of seizures in SOMA treated patients with most cases having occurred in the setting of multiple drug overdoses.
  • Most common side effects include drowsiness, dizziness and headache.

Please see accompanying full Prescribing Information

SOM1031 3/10

SOMA® 250 mg is manufactured by Meda Pharmaceuticals Inc.

Contact Meda | Privacy Policy | Site Map

Copyright ©2010 Meda Pharmaceuticals Inc. All rights reserved.